A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction

Haematologica

Volumn 99, Issue 7, 2014, Pages 1176-1183

  Komrokji, Rami S ^a   Mailloux, Adam W ^a   Chen, Dung Tsa ^a   Sekeres, Mikkael A ^b   Paquette, Ronald ^c   Fulp, William J ^a   Sugimori, Chiharu ^d   Paleveda Pena, Jennifer ^a   Maciejewski, Jaroslaw P ^d   List, Alan F ^a   Epling Burnette, Pearlie K ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; PREDNISONE; THYMOCYTE ANTIBODY; IMMUNOLOGIC FACTOR; LYMPHOCYTE ANTIBODY;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; FAINTNESS; FEMALE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; HYPOTENSION; IMMUNE DYSREGULATION; INTENTION TO TREAT ANALYSIS; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; LUNG ASPERGILLOSIS; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RESPONSE TIME; RIGOR; SERUM SICKNESS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANIMAL; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; MIDDLE AGED; MORTALITY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RABBIT; RISK FACTOR; TIME;

ADULT; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RABBITS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903639107     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.083345     Document Type: Article

References (38)

1. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008:26(15):2505-11.
2. Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP, et al. Fasmediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood. 2002;100(13):4427-32.
3. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99(3):699-705.
4. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFUGM and alterations in T-cell receptor Vbeta profiles. Br J Haematol. 1998;102(5):1314-22.
5. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79(8):1548-51.
6. Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood. 2007;110(6):1756-61.
7. Deeg HJ, Jiang PY, Holmberg LA, Scott B, Petersdorf EW, Appelbaum FR. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res. 2004;(11):1177-80.
8. Scott BL, Ramakrishnan A, Fosdal M, Storer B, Becker P, Petersdorf S, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010; 149(5):706-10.
9. Sloand EM, Olnes MJ, Shenoy A, Weinstein B, Boss C, Loeliger K, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010;28(35): 5166-73.
10. Lim ZY, Killick S, Germing U, Cavenagh J, Culligan D, Bacigalupo A, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;1(7):1436-41.
11. Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102(8):3025-7.
12. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. J Clin Oncol. 2011;29(3):303-9.
13. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003;101(6):2156-8.
14. Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004;18(3):460-5.
15. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, et al. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia. 2009;23(7):1297-302.
16. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory drugs, growth factors and epigeneticacting agents. Hematology Am Soc Hematol Educ Program. 2005:161-6.
17. Scheinberg P, Nunez O, Weinstein B, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011;365(5):430-8.
18. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000, 96(12):3671-4.
19. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570-4.
20. Sugimori C, Chuhjo T, Feng X, Yamazaki H, Takami A, Teramura M, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107(4):1308-14.
21. Asano Y, Maeda M, Uchida N, Yokoyama T, Osaki K, Shimoda K, et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol. 2001;80(11):634-8.
22. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-32.
23. Zou JX, Rollison DE, Boulware D, Chen DT, Sloand EM, Pfannes LV, et al. Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome. Leukemia. 2009;23(7):1288-96.
24. Baratti MO, Moreira YB, Traina F, Costa FF, Verjovski-Almeida S, Olalla-Saad ST. Identification of protein-coding and noncoding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts. BMC Med Genomics. 2010;3:30.
25. Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, et al. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica. 2013;98(4): 576-83.
26. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108(1):337-45.
27. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003;120(4):679-84.
28. Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C, et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol. 2002;68(4): 210-6.
29. Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, et al. Naive Tcells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. Leukemia. 2013;27(4):897-906.
30. Hohensinner PJ, Goronzy JJ, Weyand CM. Telomere dysfunction, autoimmunity and aging. Aging and disease. 2011;2(6):524-37.
31. Weyand CM, Fujii H, Shao L, Goronzy JJ. Rejuvenating the immune system in rheumatoid arthritis. Nature reviews Rheumatology. 2009;5(10):583-8.
32. Ohashi PS. T-cell signalling and autoimmunity: molecular mechanisms of disease. Nat Rev Immunol. 2002;2(6):427-38.
33. Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, et al. Telomere length in myelodysplastic syndromes. Leuk Lymphoma. 2011;52:1528-36.
34. Risitano AM. Immunosuppressive therapies in the management of acquired immune-mediated marrow failures. Curr Opin Hematol. 2012;19(1):3-13.
35. Nagaraj S, Collazo M, Corzo CA, Youn JI, Ortiz M, Quiceno D, et al. Regulatory myeloid suppressor cells in health and disease. Cancer Res. 2009;69(19):7503-6.
36. Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013; 123(11):4595-611.
37. Kordasti SY, Ingram W, Hayden J, Darling D, Barber L, Afzali B, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood. 2007; 110(3):847-50.
38. Mailloux AW, Sugimori C, Komrokji RS, Yang L, Maciejewski JP, Sekeres MA, et al. Expansion of effector memory regulatory T cells represents a novel prognostic factor in lower risk myelodysplastic syndrome. J Immunol. 2012;189(6):3198-208.